ReviewProceedings of the National Academy of Sciences of the United States of America2004
Therapeutic cancer vaccines: using unique antigens.
Review in Proceedings of the National Academy of Sciences of the United States of America, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 58 citations in OpenAlex.
- HSP-Target of Therapeutic Agents in Sepsis Treatment.International journal of molecular sciences · 2019Review
- Synthetic melanin bound to subunit vaccine antigens significantly enhances CD8+ T-cell responses.PloS one · 2017Article
- Article
- Heat-shock proteins in infection-mediated inflammation-induced tumorigenesis.Journal of hematology & oncology · 2009Review
- Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients.Cancer science · 2008Article
- Photodynamic therapy-generated vaccines: relevance of tumour cell death expression.British journal of cancer · 2007Article
- A DNA vaccine against chimeric AFP enhanced by HSP70 suppresses growth of hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2007Article
- Personalized peptide vaccines: a new therapeutic modality for cancer.Cancer science · 2006Review
- Tumor-specific therapeutic effect induced by an oncolytic adenoviral vector containing heat shock protein 70 and prodrug activation genes.Gene therapy · 2006Article
- Photodynamic therapy-generated vaccine for cancer therapy.Cancer immunology, immunotherapy : CII · 2006Article
- Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice.Cancer immunology, immunotherapy : CII · 2006Article
- Heat shock proteins HSP70 and GP96: structural insights.Cancer immunology, immunotherapy : CII · 2006Review
- Vaccinology at the beginning of the 21st century.Current opinion in immunology · 2005Review
- Vaccines: past, present and future.Nature medicine · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A decade ago, it seemed rational that our rapidly increasing knowledge of the molecular identities of tumor antigens and a deeper understanding of basic immunology would point the way to an effective therapeutic cancer vaccine. Significant progress has been made, but we do not yet have a cancer vaccine that can reliably and consistently induce tumor destruction or improve patient survival. Random mutations in cancer cells generate unique antigens in each individual, and this may be important in terms of generating a therapeutic immune response. Autologous heat shock protein-peptide complexes produced from each patient's tumor is a logical personalized approach that may obviate the need to identify the unique antigens contained in the individual vaccine. Heat shock proteins elicit adaptive and innate immune responses and have been tested in a variety of animal models and different human cancers. Activity has been seen in several animal studies. Early-phase human studies have also suggested some activity in certain cancers. Large, randomized phase 3 studies are ongoing, and these will effectively answer the question of efficacy regarding this approach to therapeutic vaccination. There are sufficient data to support the notion that cancer vaccines can induce anti-tumor immune responses in humans with cancer. How best to translate this increase in immune responsiveness to consistently and reproducibly induce objective cancer regression or increased survival remains unclear at this time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.